The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients
IMPORTANCE: The study provides valuable insights into the sociodemographic characteristics, clinical outcomes, and humoral immune response of those affected by the virus that has devastated every field of human life since 2019; the COVID-19 patients. Firstly, the association among clinical manifestations, comorbidities, and the production of neutralizing antibodies (Nabs) against SARS-CoV-2 is explored. Secondly, varying levels of Nabs among patients are revealed, and a significant correlation between the presence of Nabs and a shorter duration of hospitalization is identified, which highlights the potential role of Nabs in predicting clinical outcomes. Lastly, a follow-up conducted 7 months later demonstrates the progression and persistence of Nabs production in recovered unvaccinated individuals. The study contributes essential knowledge regarding the characteristics of the study population, the early humoral immune response, and the dynamics of Nabs production over time. These findings have significant implications for understanding the immune response to COVID-19 and informing clinical management approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Microbiology spectrum - 11(2023), 6 vom: 12. Dez., Seite e0095923 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Almeida, Dalziza Victalina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/spectrum.00959-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363051589 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363051589 | ||
| 003 | DE-627 | ||
| 005 | 20231227133040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/spectrum.00959-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM363051589 | ||
| 035 | |a (NLM)37811977 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Almeida, Dalziza Victalina |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: The study provides valuable insights into the sociodemographic characteristics, clinical outcomes, and humoral immune response of those affected by the virus that has devastated every field of human life since 2019; the COVID-19 patients. Firstly, the association among clinical manifestations, comorbidities, and the production of neutralizing antibodies (Nabs) against SARS-CoV-2 is explored. Secondly, varying levels of Nabs among patients are revealed, and a significant correlation between the presence of Nabs and a shorter duration of hospitalization is identified, which highlights the potential role of Nabs in predicting clinical outcomes. Lastly, a follow-up conducted 7 months later demonstrates the progression and persistence of Nabs production in recovered unvaccinated individuals. The study contributes essential knowledge regarding the characteristics of the study population, the early humoral immune response, and the dynamics of Nabs production over time. These findings have significant implications for understanding the immune response to COVID-19 and informing clinical management approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV-1 | |
| 650 | 4 | |a PLWH | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a pseudovirus | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Cezar, Priscila Alves |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Thais Freitas Barreto |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarz, Marcos Gustavo Araujo |e verfasserin |4 aut | |
| 700 | 1 | |a Mendonça-Lima, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Giacoia-Gripp, Carmem Beatriz Wagner |e verfasserin |4 aut | |
| 700 | 1 | |a Côrtes, Fernanda Heloise |e verfasserin |4 aut | |
| 700 | 1 | |a Lindenmeyer Guimarães, Monick |e verfasserin |4 aut | |
| 700 | 1 | |a Pilotto, Jose Henrique |e verfasserin |4 aut | |
| 700 | 1 | |a De Sá, Nathalia Beatriz Ramos |e verfasserin |4 aut | |
| 700 | 1 | |a Cazote, Andressa da Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Larissa Rodrigues |e verfasserin |4 aut | |
| 700 | 1 | |a Quintana, Marcel de Souza Borges |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro-Alves, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Coelho, Lara Esteves |e verfasserin |4 aut | |
| 700 | 1 | |a Geraldo, Kim Mattos |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Maria Pia Diniz |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Sandra Wagner |e verfasserin |4 aut | |
| 700 | 1 | |a Grinsztejn, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Veloso, Valdiléa G |e verfasserin |4 aut | |
| 700 | 1 | |a Morgado, Mariza Gonçalves |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbiology spectrum |d 2013 |g 11(2023), 6 vom: 12. Dez., Seite e0095923 |w (DE-627)NLM241847044 |x 2165-0497 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:6 |g day:12 |g month:12 |g pages:e0095923 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/spectrum.00959-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 6 |b 12 |c 12 |h e0095923 | ||